Cargando…

The impact of the recent AAP changes in palivizumab authorization on RSV-induced bronchiolitis severity and incidence

Following the most recent modification by the American Academy of Pediatrics, based on American studies on RSV epidemiology, the Italian Drug Agency (AIFA) decided to limit the total financial coverage of the palivizumab prescription by the National Health Service only to the < 29 wGA group and a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Capizzi, Antonino, Silvestri, Michela, Orsi, Andrea, Cutrera, Renato, Rossi, Giovanni A., Sacco, Oliviero
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5557508/ https://www.ncbi.nlm.nih.gov/pubmed/28807039 http://dx.doi.org/10.1186/s13052-017-0390-8

Ejemplares similares

A Systematic Review of Compliance with Palivizumab Administration for RSV Immunoprophylaxis
por: Frogel, Michael
Publicado: (2010)

Nasal Microbiota in RSV Bronchiolitis
por: Schippa, Serena, et al.
Publicado: (2020)

Clinical severity of RSV bronchiolitis
por: Hussain, Faris, et al.
Publicado: (2022)

Revised recommendations concerning palivizumab prophylaxis for respiratory syncytial virus (RSV)
por: Bollani, Lina, et al.
Publicado: (2015)

Can Resveratrol-Inhaled Formulations Be Considered Potential Adjunct Treatments for COVID-19?
por: Rossi, Giovanni A., et al.
Publicado: (2021)

Impact of Palivizumab on RSV Hospitalizations for Children with Hemodynamically Significant Congenital Heart Disease
por: Chang, Ruey-Kang R., et al.
Publicado: (2009)

Review of palivizumab in the prophylaxis of respiratory syncytial virus (RSV) in high-risk infants
por: Mejías, Asunción, et al.
Publicado: (2008)

Palivizumab reimbursement criteria and neonatal RSV hospitalisation: a regional retrospective review
por: Belleudi, Valeria, et al.
Publicado: (2021)

Compliance with The RSV Immunoprophylaxis Dosing Schedule in The Polish Registry for Palivizumab (2008-2014)
por: Borecka, Róża, et al.
Publicado: (2019)

Impact of the 2014 American Academy of Pediatrics recommendation and of the resulting limited financial coverage by the Italian Medicines Agency for palivizumab prophylaxis on the RSV-associated hospitalizations in preterm infants during the 2016–2017 epidemic season: a systematic review of seven Italian reports
por: Cutrera, Renato, et al.
Publicado: (2019)

The Contribution of Neutrophils to the Pathogenesis of RSV Bronchiolitis
por: Sebina, Ismail, et al.
Publicado: (2020)

Eosinophil Cationic Protein and Chemokines in Nasopharyngeal Secretions of Infants with Respiratory Syncytial Virus (RSV) Bronchiolitis and Non-RSV Bronchiolitis
por: Kim, Hyun Hee, et al.
Publicado: (2007)

Recurrent respiratory infections in the follow-up of the extremely low birth weight infant
por: Sacco, Oliviero, et al.
Publicado: (2015)

Effectiveness of Palivizumab in Preventing RSV Hospitalization in High Risk Children: A Real-World Perspective
por: Homaira, Nusrat, et al.
Publicado: (2014)

Review of the Safety, Efficacy and Tolerability of Palivizumab in the Prevention of Severe Respiratory Syncytial Virus (RSV) Disease
por: O’Hagan, Shaun, et al.
Publicado: (2023)

Emergency Department Septic Screening in Respiratory Syncytial Virus (RSV) and Non-RSV Bronchiolitis
por: Chee, Chris, et al.
Publicado: (2010)

Cost Analysis of an Antimicrobial Stewardship Program (ASP) Protocol for Adherence to the 2014 American Academy of Pediatrics (AAP) Palivizumab Prophylaxis Recommendations in a Freestanding Children’s Hospital
por: Hines, Andrea Green, et al.
Publicado: (2017)

Impact of the Withdrawal of Palivizumab Immunoprophylaxis on the Incidence of Respiratory Syncytial Virus (RSV) Hospitalizations Among Infants Born at 33 to 35 Weeks’ Gestational Age in the Province of Quebec, Canada: The RSV-Quebec Study
por: Papenburg, Jesse, et al.
Publicado: (2020)

The Differences Between RSV and no RSV Acute Bronchiolitis in Hospitalized Infants: A Cross-Sectional Study
por: Christou, Evangelos, et al.
Publicado: (2022)

The Use of Albuterol in Young Infants Hospitalized with Acute RSV Bronchiolitis
por: Del Vecchio, Michael T., et al.
Publicado: (2012)

Respiratory syncytial virus (RSV) and its propensity for causing bronchiolitis
por: Pickles, Raymond J, et al.
Publicado: (2015)

Prevalence of infant bronchiolitis‐coded healthcare encounters attributable to RSV
por: Turi, Kedir N., et al.
Publicado: (2018)

Nasal and Fecal Microbiota and Immunoprofiling of Infants With and Without RSV Bronchiolitis
por: Alba, Claudio, et al.
Publicado: (2021)

Respiratory Syncytial Virus-associated hospitalization in premature infants who did not receive palivizumab prophylaxis in Italy: a retrospective analysis from the Osservatorio Study
por: Silvestri, Michela, et al.
Publicado: (2016)

Palivizumab: a review of its use in the protection of high risk infants against respiratory syncytial virus (RSV)
por: Geskey, Joseph M, et al.
Publicado: (2007)

A comparative study of respiratory syncytial virus (RSV) prophylaxis in premature infants within the Canadian Registry of Palivizumab (CARESS)
por: Paes, B., et al.
Publicado: (2012)

Association of RSV-related hospitalization and non-compliance with Palivizumab among commercially insured infants: a retrospective claims analysis
por: Stewart, Dan L, et al.
Publicado: (2013)

RSV-related hospitalization and outpatient palivizumab use in very preterm (born at <29 wGA) infants: 2003-2020
por: Packnett, Elizabeth R., et al.
Publicado: (2022)

The amino acid permease (AAP) genes CsAAP2A and SlAAP5A/B are required for oomycete susceptibility in cucumber and tomato
por: Berg, Jeroen A., et al.
Publicado: (2021)

High frequency oscillatory ventilation for respiratory failure due to RSV bronchiolitis
por: Berner, Michel E., et al.
Publicado: (2008)

Bronchiolitis guidelines: what about the Italian situation in a primary care setting?
por: Porcaro, Federica, et al.
Publicado: (2023)

AAPS 2017 Abstract Supplement
Publicado: (2017)

The Medicaid Cost of Palivizumab
por: Ambrose, Christopher S., et al.
Publicado: (2015)

Reformatting palivizumab and motavizumab from IgG to human IgA impairs their efficacy against RSV infection in vitro and in vivo
por: Jacobino, Shamir R., et al.
Publicado: (2018)

Risk Factors of Very Severe RSV Infections in a Multicenter Cohort of Very Preterm and Extreme Preterm Babies Receiving or Not Palivizumab
por: Mulot, Gwenaelle, et al.
Publicado: (2022)

Computerized acoustic assessment of treatment efficacy of nebulized epinephrine and albuterol in RSV bronchiolitis
por: Beck, Raphael, et al.
Publicado: (2007)

Effect of inhaled nitric oxide on respiratory mechanics in ventilated infants with RSV bronchiolitis
por: Patel, N. R., et al.
Publicado: (1999)

TLR4 Gene Polymorphisms Interaction With Ascaris Infection in Severe RSV Bronchiolitis
por: Buendía, Jefferson Antonio, et al.
Publicado: (2022)

AAPS and PSRC 2016 Abstract Supplement
Publicado: (2016)

A population-weighted, condition-adjusted estimate of palivizumab efficacy in preventing RSV-related hospitalizations among US high-risk children
por: Ambrose, Christopher S, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_npr7r8hder67ok0iqeknpai0bm